Sanofi and Regeneron’s dupilumab has been given a priority review by the FDA, putting the first-in-class drug on course for a likely approval by 29 March. The drug is for adult patients with ...

Sanofi’s move for Dren Bio’s clinical asset boosts its immunology-focused strategy of becoming a leader in the field.

Regeneron Pharmaceuticals and Sanofi have announced more positive results for their novel drug dupilumab in the allergic inflammatory arena. Their phase IIa proof-of-concept study of dupilumab ...

Dupilumab added to standard COPD triple therapy reduces the annual rate of moderate exacerbations but not severe exacerbations.

1 Dupilumab Development Program Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 ...

Regeneron Pharmaceuticals, Inc. and Sanofi announced that the FDA has accepted a supplemental Biologics License Application for Dupixent (dupilumab) to treat adults with bullous pemphigoid (BP), a ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than ...

In a phase 4 trial, dupilumab effectively reduces airway inflammation and mucus plugging, improving lung function and asthma control in patients with moderate to severe type 2 asthma.

By targeting the IL-4 beta receptor and IL-13, the researchers said, dupilumab (Dupixent; Sanofi, Regeneron) manages atopic dermatitis and improves depression and anxiety, but evidence about its ...

and Sanofi today presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the investigational use of Dupixent ® (dupilumab) in adults with moderate-to-severe bullous ...